November 26, 2018 7:38am

… As the NASDAQ roars with the question, will the “pet” algorithms play together?

Out and about: Tasly Pharmaceutical Group and Mesoblast Limited (MESO; ASX: MSB) first Joint Steering Committee (JSC) met for their cardiovascular partnership was held in Tianjin last week, and as a result Tasly plans to meet with the National Medical Products Administration (NMPA) of China  (formerly known as the China FDA) in the Q1/19 to discuss the regulatory approval pathway for MESO’s heart failure product candidate MPC-150-IM in China.  Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) announced the initiation of a P1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection.

 

Pre-open indications: I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

A trusted source of factual reporting of preludes and aftermaths!

 

There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?

 

U.S. stock index futures are headed north …

Dow futures are UP +1.07% (+260 points) and NASDAQ futures are UP +1.57% (+103 points)

 

U.S. stock futures pointed to a higher open on the first trading day of the week;

European markets rise after EU backs PM May's Brexit deal;

Asia markets were mixed on Monday as energy stocks declined after oil prices fell last week to their lowest levels in more than a year.

 

Data docket: Chicago Federal Reserve national activity index numbers are due at 8:30 a.m. ET, while Dallas Fed manufacturing survey data are due to be released at 10:30 a.m. ET.

 

Monday’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is NOT indicating

  • The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +1.17% UPSIDE

  • The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

  • The iShares Russell 2000 (IWM) is indicating a POSITIVE +1.22% UPSIDE

 

Henry’omics:

WATCH the first hour …

Will Friday’s positive sentiment be maintained after the close was positive with an Advance/Decline Line (A/DL) of 27/17 and 1 flat?

Friday’s closing bell: “the high and the low of it. Upside strength was dollar strong but downside weakness was cents weak.” Volume HAD said it all: 0 out of the 27 upside had higher (than the 3 month average) volume and 2 out of 17 downside experienced greater volume (than the 3 month average).

 

Friday night’s percentage (%) indicators:

  • Review the range of the 27 upside from +0.08% (FATE) to +5.17% (BSTG) while the 17 downside ranged from -09.8% (CUR) to -6.26% (BLCM) with a 1 flat close (RENE.L).

Volume stat:

  • 0 out of 27 upside had higher (than the 3 month average) volume;
  • 2 out of 17 downside experienced greater volume (than the 3 month average).

The iShares NASDAQ Biotechnology (IBB) in a week’s history lesson; a five session aggregate of a negative -1.73% after 2 downside sessions out of 4 and 1 holiday!

  • In 17 sessions in November – there were 1 holiday, 7 positive closes, 1 neutral and 8 negative closes
  • In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
  • In 19 sessions in September – there were 10 negative closes and 9 positive sessions;
  • In 21 August sessions – 6 had negative and 15 had positive closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

News usually generates +positive+ price action:

Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The commencement of first-in-human dosing marks the first clinical use of Alnylam’s Enhanced Stabilization Chemistry-Plus (ESC+) GalNAc conjugate delivery platform and the start of Vir’s first global development program. VIR-2218 was originated by Alnylam as ALN-HBV02 and was licensed to Vir, which will conduct its clinical development.

Tasly Pharmaceutical Group and Mesoblast Limited (MESO; ASX: MSB) announced that the first Joint Steering Committee (JSC) meeting for their cardiovascular partnership was held in Tianjin last week, and as a result Tasly plans to meet with the National Medical Products Administration (NMPA) of China (formerly known as the China FDA) in the Q1/19 to discuss the regulatory approval pathway for MESO’s heart failure product candidate MPC-150-IM in China.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.